Truist Securities Starts Alnylam Pharmaceuticals (ALNY) at Buy

Truist Securities analyst Danielle Brill initiates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Buy rating and a price target of $385.00.

The analyst comments " Initiate ALNY w/ BUY: Amvuttra Launch Looks On-Track To Surpass High Expectations, Both Near & Long Term - Key near-term value driver is the Amvuttra launch in TTR-CM, which seems to be off to a strong start. Based on KOL feedback, survey work, and 3rd party sales data, we think Amvuttra is tracking well ahead of guidance and will significantly beat 2Q estimates. Although the stock has been strong ahead of the print, we believe ALNY is a name investors want to own in the current environment, and we think the stock will continue to outperform with strong launch execution. ALNY's pipeline (most notably zilebesiran) is still potential upside to our model and could represent another blockbuster opportunity; de-risking data expected 2H25. Initiate with a BUY and a $385 PT."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $320.53 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results